Physician profile
Michael B Ross
NPI 1821048323
$543.73
in general payments reported to CMS, 2019-2025
15 companies · $60.28 in 2025
The $60.28 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $51.73 · 2021: $148 · 2022: $12.03 · 2023: $84.86 · 2025: $60.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $135.92 | 2021 | |
| Janssen Biotech, INC. | $82.90 | 2019-2023 | Imbruvica |
| Gilead Sciences, INC. | $61.24 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $38.10 | 2019 | |
| Astellas Pharma US INC | $34.17 | 2025 | Padcev |
| Pfizer INC. | $28.14 | 2020 | |
| Kite Pharma, INC. | $27.58 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $25.84 | 2023 | Epkinly, Imbruvica |
| Ipsen Biopharmaceuticals, INC | $23.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.48 | 2019 | |
| Merck Sharp & Dohme LLC | $14.58 | 2019 | |
| Secura Bio, INC. | $14.19 | 2023 | Copiktra |
| Seagen INC. | $12.67 | 2019 | |
| Amgen INC. | $12.03 | 2022 | |
| Lilly USA, LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.